Dr. Afshin Rashtian is the Medical Director of Radiation Oncology at The Cancer Center Riverside Community Hospital. He also serves as the Medical Director of The Cyberknife Center at Riverside Community Hospital. Previous to joining Riverside Community Hospital, he served as Assistant Professor of Clinical Radiation Oncology at USC/Norris Cancer Hospital and USC/LAC. He also served as the Associate Program Director of the Residency program at USC as well as the Medical School Clerkship Director. He was also the RTOG (Radiation Therapy Oncology Group) representative for USC. He attended Medical School at The George Washington University School of Medicine in Washington DC where he earned his M.D. degree. Dr. Rashtian did his internship in Internal Medicine at Cedars Sinai Medical Center in Los Angeles and his training in Radiation Oncology at the Southern California Permanente Medical Group in Los Angeles.
He has been involved in several research projects and was asked to give an oral presentation at the ASTRO (American Society of Therapeutic Radiology & Oncology) meeting regarding his research in breast cancer. He has also had several presentations at ASTRO regarding his research in lung cancer, breast cancer, sarcoma, and CNS. Dr. Rashtian’s expertise includes treating malignancies of the Lung, Head & Neck, Breast, CNS, Prostate, GI, Gyn, and Sarcoma. Additionally, he has a special interest in utilizing Stereotactic Body Radiation Therapy (SBRT) in treating malignancies with the Cyberknife Stererotactic Radiosugery System. Dr. Rashtian uses the latest state of the art technology in treating his patients using IMRT (Intensity Modulated Radiation Therapy), IGRT (Image Guided Radiation Therapy), HDR Brachytherapy, and 4D-CT. Dr. Rashtian is a leader in the field of radiation oncology with a strong national reputation. He has given talks at both the regional and national stage. He hopes to bring his academic background and expertise to the Inland Empire at Riverside Community Hospital and provide the latest technical and clinical advances the field has to offer.